Project Grant R21AG103663
Award Date 9/1/26
Completion Date 5/31/28
Dollars Obligated $246K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
University City, MO 63130, USA
Similar Awards
- The National Institute on Aging awarded The Washington University $651,035 on August 15, 2026, under the Aging Research program (CFDA 93.866) to develop predictive markers for amyloid-related imaging abnormalities in Alzheimer's disease patients treated with amyloid-targeted therapies. The project integrates data from two complementary cohorts: the Dominantly Inherited Alzheimer Network Trials Unit, the longest-treated anti-amyloid cohort with harmonized clinical, imaging, and biomarker data and...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded The Washington University $3,188,901 under the Aging Research program (CFDA 93.866) for a four-year project beginning September 1, 2025, and concluding August 31, 2029. This project grant supports research to map amyloid, tau, and neurodegeneration (ATN) biomarkers in relation to neuropsychiatric phenotypes and genotypes across the Alzheimer's disease continuum using machine learning methodologies. The research...
- The National Institute on Aging awarded The Washington University $129,876 under the Aging Research program (CFDA 93.866) on June 15, 2026, to investigate the relationship between tau accumulation, white matter degeneration, and cognition in preclinical Alzheimer disease. The funded research uses autosomal dominant Alzheimer disease (ADAD) cohorts enrolled in the Dominantly Inherited Alzheimer Network (DIAN) to examine how tau tangle accumulation and white matter microstructural damage precede...
- The National Institute on Aging awarded The Washington University $642,991 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate genetic drivers of phenotypic variability in autosomal dominant Alzheimer's disease using a multi-omics approach. The research identifies genetic alterations associated with Alzheimer's disease risk and presentation in individuals carrying mutations in the PSEN1, APP, and PSEN2 genes. The project characterizes transcriptomic brain profiles...
- The National Institute on Aging, a component of the Department of Health and Human Services, awarded Massachusetts Institute of Technology $596,050 on September 15, 2026, under the Aging Research program (CFDA 93.866) to investigate fuzzy coat dynamics of post-translationally modified tau aggregation. The project examines structural properties of tau, a microtubule-associated protein whose aggregation hallmarks Alzheimer's disease and twenty other neurodegenerative diseases. The research tests...
- The National Institute on Aging awarded the University of California, Berkeley $549,260 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop advanced large language model-based AI tools that enhance precision in predicting Alzheimer's disease pathology and cognitive outcomes. The research addresses critical gaps in precision medicine for Alzheimer's disease, particularly the need to capture patient heterogeneity, accurately identify treatment candidates for...
- The National Institute on Aging awarded The Washington University $1,366,056 on January 1, 2026, under the Aging Research program (CFDA 93.866) to develop a biocompatible fiber implant for long-term deep-brain imaging and manipulation in mouse models of Alzheimer disease. The implant integrates photoacoustic microscopy and two-photon microscopy for simultaneous functional and molecular imaging, along with microelectrode-based neural stimulation and microfluidics-based drug delivery to create a...
- The National Institute on Aging awarded The Washington University $150,114 on March 18, 2026, under the Aging Research program (CFDA 93.866) to investigate the role of brain-engrafted monocyte-derived macrophages in Alzheimer's disease. The research examines how monocyte-derived macrophages infiltrating the brain contribute to Alzheimer's disease pathology. The F99 phase involves assessing the effects of promoting or depleting brain-engrafted monocyte-derived macrophages on amyloid plaque...
- The National Institute on Aging awarded New York University $6.203 million on September 15, 2025, under the Aging Research program (CFDA 93.866) to examine peripheral immune markers and vascular dysfunction as contributors to cognitive decline and Alzheimer's disease. The research integrates circulating biomarkers—platelet aggregation, neutrophil activity, and proteomic data—with advanced imaging to assess associations between vascular and immune dysfunction and cerebrovascular burden, amyloid...
- The National Institute on Aging awarded Purdue University $387,183 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop mass spectrometry-based proteomics strategies examining post-translational modifications related to protein aggregation and extracellular vesicle-mediated propagation in neurodegenerative disease, with emphasis on Alzheimer's disease. The recipient will establish a novel proteomics platform to profile N-terminal acetylation landscapes in primary...